SM
ARDS

Sabby Management’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Sabby Management’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,140,174
Closed -$672K – 113
2023
Q1 		$672K Buy
+2,140,174
New +$1.55M 0.59% 16

Other funds holding ARDS

Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Sabby Management's ARDS Position: Q2 2023 in Review

Sabby Management sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q2 2023, closing a stake of 2,140,174 shares — an estimated $672K sold.

Sabby Management first reported a position in ARDS in Q1 2023 and held it in 1 quarter. The position peaked at $672K in Q1 2023. 18 funds tracked by Wall St. Rank hold ARDS as of Q2 2023.

  • Sabby Management reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Sabby Management sold 2,140,174 Aridis Pharmaceuticals Inc. Common Stock shares in Q2 2023, an estimated $672K.
  • Sabby Management first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Sabby Management's Aridis Pharmaceuticals Inc. Common Stock position peaked at $672K in Q1 2023.
  • 18 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q2 2023.

Based on Sabby Management's 13F filing for Q2 2023, filed 14 Aug 2023.